Securities Fraud Class Action Filed Against ADMA Biologics
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Globenewswire
- Lawsuit Background: A class action lawsuit has been filed against ADMA Biologics (NASDAQ: ADMA) for securities fraud, alleging significant misstatements and omissions in financial reporting during the period from August 9, 2024, to March 25, 2026, which undermines investor confidence.
- Key Allegations: The lawsuit claims that ADMA engaged in undisclosed related party transactions and used channel stuffing to inflate revenues, lacking adequate internal controls, which rendered the company's positive business outlook misleading and potentially harmful to investors.
- Stock Price Reaction: Following a report by Culper Research on March 24, 2026, alleging channel stuffing, ADMA's stock price plummeted by $3.96, or 29.1%, over two trading days, closing at $9.63 per share, indicating severe market concerns regarding the company's financial health.
- Investor Action: Affected investors must file for lead plaintiff status by August 10, 2026, to represent other investors in the lawsuit, with KTMC offering free case evaluations, emphasizing that there are no costs involved for investors during this process.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ADMA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ADMA
About ADMA
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Securities Fraud Class Action Filed Against ADMA Biologics
- Lawsuit Background: A class action lawsuit has been filed against ADMA Biologics (NASDAQ: ADMA) for securities fraud, alleging significant misstatements and omissions in financial reporting during the period from August 9, 2024, to March 25, 2026, which undermines investor confidence.
- Key Allegations: The lawsuit claims that ADMA engaged in undisclosed related party transactions and used channel stuffing to inflate revenues, lacking adequate internal controls, which rendered the company's positive business outlook misleading and potentially harmful to investors.
- Stock Price Reaction: Following a report by Culper Research on March 24, 2026, alleging channel stuffing, ADMA's stock price plummeted by $3.96, or 29.1%, over two trading days, closing at $9.63 per share, indicating severe market concerns regarding the company's financial health.
- Investor Action: Affected investors must file for lead plaintiff status by August 10, 2026, to represent other investors in the lawsuit, with KTMC offering free case evaluations, emphasizing that there are no costs involved for investors during this process.
See More
ADMA Biologics Faces Class Action Over Alleged Internal Control Failures
- Lawsuit Background: ADMA Biologics is facing a class action lawsuit for alleged securities fraud during the period from August 9, 2024, to March 25, 2026, claiming false statements regarding the effectiveness of internal controls led to investor losses.
- Revenue Growth Dispute: A March 2026 research report alleged that ADMA's reported 20% revenue growth was fictitious, estimating actual growth at negative 3%, which directly impacts investors' perceptions of the company's financial health.
- Internal Control Failures: The lawsuit asserts that ADMA certified its disclosure controls as effective across seven consecutive SEC filings while concealing related party transactions with
See More
ADMA Biologics Investors Class Action Lawsuit Announced
- Class Action Notice: The Portnoy Law Firm informs ADMA Biologics investors of a class action lawsuit for those who purchased securities between August 9, 2024, and March 25, 2026, with a deadline of August 10, 2026, to file a lead plaintiff motion to protect their legal rights.
- Legal Allegations: The complaint alleges that ADMA and certain executives failed to disclose material information in the Offering Documents, violating federal securities laws, including undisclosed related party transactions, channel stuffing to create an appearance of revenue, and inadequate internal controls, leading to investor losses.
- Investor Damages: When the true details emerged in the market, investors suffered damages due to ADMA's false and misleading statements, indicating that the company's representations about its business, operations, and prospects were materially false and misleading at all relevant times.
- Law Firm Background: The founding partner of the Portnoy Law Firm has recovered over $5.5 billion for aggrieved investors, showcasing their extensive experience and success in handling such cases, allowing investors to seek legal support to recover their losses.
See More
ADMA Biologics Class Action Lawsuit Notice
- Class Action Initiation: ADMA Biologics faces a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with the class period from August 9, 2024, to March 25, 2026, requiring investors to apply as lead plaintiffs by August 10, 2026, which could impact the company's reputation and stock price.
- False Statement Allegations: The lawsuit alleges that ADMA Biologics made false or misleading statements during the class period, including undisclosed related party transactions and channel stuffing practices, potentially leading to decreased investor confidence and stock price volatility.
- Stock Price Volatility: According to the complaint, ADMA Biologics' stock price fell over 16% following the release of a report by Culper Research on March 24, 2026, and dropped again by over 13% after the company's response, indicating market concerns regarding the company's financial transparency.
- Law Firm Background: Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder rights litigation, recovering over $916 million for investors in 2025, showcasing its strength in securities class actions, which may influence ADMA's legal strategy.
See More
ADMA Biologics Faces Class Action Lawsuit
- Lawsuit Background: Kahn Swick & Foti, LLC is representing investors in a class action lawsuit against ADMA Biologics, Inc., aiming to recover losses for those who purchased the company's securities between August 9, 2024, and March 25, 2026, reflecting significant investor dissatisfaction with the company's transparency.
- Allegations: The lawsuit alleges that ADMA and certain executives failed to disclose material information in the Offering Documents, including undisclosed related party transactions and channel stuffing to create a false appearance of revenue, indicating serious misconduct in financial reporting that may have led to substantial investor losses.
- Legal Proceedings: The case is pending in the United States District Court for the District of New Jersey, with investors required to apply by August 10, 2026, to be appointed as lead plaintiffs, suggesting that active participation in the legal process could influence the outcome of potential recoveries.
- Law Firm Background: Kahn Swick & Foti, LLC is one of the nation's premier boutique securities litigation law firms, ranked among the top ten nationally based on total settlement value in the past year, demonstrating its expertise and influence in handling investor claims.
See More
Class Action Lawsuit Filed Against ADMA Biologics
- Class Action Initiation: Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased ADMA Biologics securities between August 9, 2024, and March 25, 2026, alleging that the company made materially false and misleading statements during this period, resulting in investor losses.
- Details of Allegations: The lawsuit claims that ADMA Biologics engaged in undisclosed related party transactions and used channel stuffing to create a false appearance of revenue, while lacking adequate internal controls, which severely impacted the company's business outlook and investor confidence.
- Investor Rights Protection: Investors participating in the lawsuit can seek compensation without any upfront costs through a contingency fee arrangement, and those affected are encouraged to apply to be lead plaintiffs by August 10, 2026, to represent other investors in the litigation.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, demonstrating its expertise and successful track record in this field.
See More
Securities Fraud Class Action Filed Against ADMA Biologics
- Lawsuit Background: A class action lawsuit has been filed against ADMA Biologics (NASDAQ: ADMA) for securities fraud, alleging significant misstatements and omissions in financial reporting during the period from August 9, 2024, to March 25, 2026, which undermines investor confidence.
- Key Allegations: The lawsuit claims that ADMA engaged in undisclosed related party transactions and used channel stuffing to inflate revenues, lacking adequate internal controls, which rendered the company's positive business outlook misleading and potentially harmful to investors.
- Stock Price Reaction: Following a report by Culper Research on March 24, 2026, alleging channel stuffing, ADMA's stock price plummeted by $3.96, or 29.1%, over two trading days, closing at $9.63 per share, indicating severe market concerns regarding the company's financial health.
- Investor Action: Affected investors must file for lead plaintiff status by August 10, 2026, to represent other investors in the lawsuit, with KTMC offering free case evaluations, emphasizing that there are no costs involved for investors during this process.
See More
ADMA Biologics Faces Class Action Over Alleged Internal Control Failures
- Lawsuit Background: ADMA Biologics is facing a class action lawsuit for alleged securities fraud during the period from August 9, 2024, to March 25, 2026, claiming false statements regarding the effectiveness of internal controls led to investor losses.
- Revenue Growth Dispute: A March 2026 research report alleged that ADMA's reported 20% revenue growth was fictitious, estimating actual growth at negative 3%, which directly impacts investors' perceptions of the company's financial health.
- Internal Control Failures: The lawsuit asserts that ADMA certified its disclosure controls as effective across seven consecutive SEC filings while concealing related party transactions with
See More
ADMA Biologics Investors Class Action Lawsuit Announced
- Class Action Notice: The Portnoy Law Firm informs ADMA Biologics investors of a class action lawsuit for those who purchased securities between August 9, 2024, and March 25, 2026, with a deadline of August 10, 2026, to file a lead plaintiff motion to protect their legal rights.
- Legal Allegations: The complaint alleges that ADMA and certain executives failed to disclose material information in the Offering Documents, violating federal securities laws, including undisclosed related party transactions, channel stuffing to create an appearance of revenue, and inadequate internal controls, leading to investor losses.
- Investor Damages: When the true details emerged in the market, investors suffered damages due to ADMA's false and misleading statements, indicating that the company's representations about its business, operations, and prospects were materially false and misleading at all relevant times.
- Law Firm Background: The founding partner of the Portnoy Law Firm has recovered over $5.5 billion for aggrieved investors, showcasing their extensive experience and success in handling such cases, allowing investors to seek legal support to recover their losses.
See More
ADMA Biologics Class Action Lawsuit Notice
- Class Action Initiation: ADMA Biologics faces a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with the class period from August 9, 2024, to March 25, 2026, requiring investors to apply as lead plaintiffs by August 10, 2026, which could impact the company's reputation and stock price.
- False Statement Allegations: The lawsuit alleges that ADMA Biologics made false or misleading statements during the class period, including undisclosed related party transactions and channel stuffing practices, potentially leading to decreased investor confidence and stock price volatility.
- Stock Price Volatility: According to the complaint, ADMA Biologics' stock price fell over 16% following the release of a report by Culper Research on March 24, 2026, and dropped again by over 13% after the company's response, indicating market concerns regarding the company's financial transparency.
- Law Firm Background: Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder rights litigation, recovering over $916 million for investors in 2025, showcasing its strength in securities class actions, which may influence ADMA's legal strategy.
See More
ADMA Biologics Faces Class Action Lawsuit
- Lawsuit Background: Kahn Swick & Foti, LLC is representing investors in a class action lawsuit against ADMA Biologics, Inc., aiming to recover losses for those who purchased the company's securities between August 9, 2024, and March 25, 2026, reflecting significant investor dissatisfaction with the company's transparency.
- Allegations: The lawsuit alleges that ADMA and certain executives failed to disclose material information in the Offering Documents, including undisclosed related party transactions and channel stuffing to create a false appearance of revenue, indicating serious misconduct in financial reporting that may have led to substantial investor losses.
- Legal Proceedings: The case is pending in the United States District Court for the District of New Jersey, with investors required to apply by August 10, 2026, to be appointed as lead plaintiffs, suggesting that active participation in the legal process could influence the outcome of potential recoveries.
- Law Firm Background: Kahn Swick & Foti, LLC is one of the nation's premier boutique securities litigation law firms, ranked among the top ten nationally based on total settlement value in the past year, demonstrating its expertise and influence in handling investor claims.
See More
Class Action Lawsuit Filed Against ADMA Biologics
- Class Action Initiation: Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased ADMA Biologics securities between August 9, 2024, and March 25, 2026, alleging that the company made materially false and misleading statements during this period, resulting in investor losses.
- Details of Allegations: The lawsuit claims that ADMA Biologics engaged in undisclosed related party transactions and used channel stuffing to create a false appearance of revenue, while lacking adequate internal controls, which severely impacted the company's business outlook and investor confidence.
- Investor Rights Protection: Investors participating in the lawsuit can seek compensation without any upfront costs through a contingency fee arrangement, and those affected are encouraged to apply to be lead plaintiffs by August 10, 2026, to represent other investors in the litigation.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, demonstrating its expertise and successful track record in this field.
See More
